| Name | Title | Contact Details |
|---|
ImprimisRx® is a pharmaceutical company dedicated to delivering high-quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high-quality formulations that are supported by the clinical experience of physicians and their patients. We offer proprietary compounded ophthalmic formulations. All of our innovative drug formulations are born from the clinical experience of physicians and pharmacist formulators. We are focused on people, and believe our unique business model provides us with the opportunity to address unmet patient needs while delivering high quality and affordable medical solutions to physicians and patients.
Quip is the oral care company designing and delivering products, advice and professional services to make oral health more simple, accessible, and enjoyable.
Edmund Optics (EO) has been a leading supplier of precision optics and optical components since 1942, designing and manufacturing a wide array of multi-element optical lenses, lens coatings, imaging systems, and optomechanical equipment. Led by a staff of skilled optical engineers and scientists, EO is application focused and pursues new ways to implement optical technology, enabling advancements in industrial metrology, semiconductor manufacturing, life sciences, and more. EO is a worldwide presence in industrial optics extending well beyond our original manufacturing plant and corporate headquarters in Barrington, New Jersey, USA.
Since 2001, Regent Surgical Health has led the way in developing and managing successful surgery center partnerships. The ASC model is constantly evolving and Regent positions our facility partners to meet these changing market conditions and succeed. Today, a vast majority of our partnerships are Physician/Hospital Joint Ventures. Our experience has led us to develop proprietary ownership models that give both doctors and hospital administrators what they need to ensure long term clinical and financial success. Our success had earned us a reputation as Joint Venture Specialists. Regent has extensive knowledge of the ASC marketplace. We have found successful financial solutions to increase net revenues rather than using out of network strategies, pioneered new procedures such as spine, cardiology, gastric banding, and knee replacements into the ASC environment, and developed both majority and minority hospital partnerships. At Regent, our track record for successful ASC Turnarounds, De Novos, and Joint Ventures is unmatched.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.